These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 26907504

  • 1. Cost-effectiveness of Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the Republic of Korea.
    Park HY, Ku HM, Sohn HS, Seo HS, Yung Lee H, Hwa Lim K, Kwon JW.
    Clin Ther; 2016 Mar; 38(3):655-67.e1-2. PubMed ID: 26907504
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D, Dass R, Hettle R.
    BMC Health Serv Res; 2017 Mar 08; 17(1):182. PubMed ID: 28270207
    [Abstract] [Full Text] [Related]

  • 3. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 08; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q, Ming WK, Yip WY, You JHS.
    Int J Infect Dis; 2019 Jan 08; 78():44-49. PubMed ID: 30342251
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015 Jan 08; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 6. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 08; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 7. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
    Lu X, Smare C, Kambili C, El Khoury AC, Wolfson LJ.
    BMC Health Serv Res; 2017 Jan 26; 17(1):87. PubMed ID: 28122562
    [Abstract] [Full Text] [Related]

  • 8. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH, Kwon OJ, Kim YS, Park MS, Hwang S, Shim TS.
    Respir Investig; 2020 Jan 26; 58(1):45-51. PubMed ID: 31635903
    [Abstract] [Full Text] [Related]

  • 9. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany.
    Wolfson LJ, Gibbert J, Wirth D, Diel R.
    Eur Respir J; 2015 Dec 25; 46(6):1826-9. PubMed ID: 26493796
    [No Abstract] [Full Text] [Related]

  • 11. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 25; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 12. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.
    Kunkel A, Cobelens FG, Cohen T.
    PLoS Med; 2016 Oct 25; 13(10):e1002142. PubMed ID: 27727274
    [Abstract] [Full Text] [Related]

  • 13. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 14. Comparison of Effectiveness Between Delamanid and Bedaquiline Among Patients with Multidrug-Resistant Tuberculosis: A Markov Model Simulation Study.
    Byun JH, Park JA, Kang HR, Shin JY, Lee EK.
    Clin Drug Investig; 2016 Nov 01; 36(11):957-968. PubMed ID: 27465204
    [Abstract] [Full Text] [Related]

  • 15. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP, Klaassen F, Sweeney S, Furin J, Franke MF, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies NA.
    PLoS Med; 2024 May 01; 21(5):e1004401. PubMed ID: 38701084
    [Abstract] [Full Text] [Related]

  • 16. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany.
    Diel R, Hittel N, Schaberg T.
    Respir Med; 2015 May 01; 109(5):632-41. PubMed ID: 25862597
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
    Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.
    Eur Respir J; 2017 May 01; 49(5):. PubMed ID: 28529205
    [Abstract] [Full Text] [Related]

  • 18. Bedaquiline-based treatment for extensively drug-resistant tuberculosis in South Africa: A cost-effectiveness analysis.
    Fekadu G, Yao J, You JHS.
    PLoS One; 2022 May 01; 17(8):e0272770. PubMed ID: 35930574
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB, Karaoui LR, Mansour H.
    Ann Pharmacother; 2014 Jan 01; 48(1):107-15. PubMed ID: 24259600
    [Abstract] [Full Text] [Related]

  • 20. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov 01; 52(11):129-32. PubMed ID: 25395481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.